WelChol approved by FDA to aid glycemic control in diabetics

WASHINGTON Daiichi Sankyo has received approval from the Food and Drug Administration for its application for WelChol tablets to improve glycemic control.

WelChol (colesevelam hydrochloride) is indicated as an adjunct to diet and exercise for adults with Type 2 diabetes.

WelChol had already been approved by the FDA for lowering cholesterol. WelChol is nonsystemic, unlike many cholesterol drugs, which means it isn't absorbed by the body and does not pass through the kidneys or liver.